Avrobio shifts gene therapy priorities as data surprise shelves lead program


dna, genomics

Avrobio is stopping enrollment in a clinical trial for its Fabry disease program after new results showed variability in how the gene therapy was taken up by patients. No safety problems were reported, but the biotech said it now plans to focus its other gene therapy candidates for rare metabolic disorders.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.